Family History of Ovarian Cancer Linked to Breast Cancer Risk
A team of researchers sought to evaluate familial risks of developing breast cancer among women with a family history of cancers other than breast cancer.
Ovarian Cancer
Oral Contraceptives Protect Against Ovarian, Endometrial Cancer
Oral contraceptives have a lasting protective effect against ovarian and endometrial cancer, according to a new study.
Guidance for the Diagnosis and Management of Ovarian Cysts
The risk of developing benign ovarian cysts is up to 90% for premenopausal women and 75% for postmenopausal women.
CA125 Can Detect Ovarian Cancer in General Practice
And elevated CA125 indicates higher risk for other cancers, especially in women aged ≥50 years.
PTSD Symptoms Tied to Higher Risk for Ovarian Cancer
Correlation moderately attenuated after adjustment for health and ovarian cancer risk factors.
Intrauterine Device Use May Reduce Incidence of Ovarian Cancer
Novel noncontraceptive benefit seen for all intrauterine devices.
Zejula Gets Priority Review for Late Stage Ovarian Cancer Indication
The sNDA is supported by data from the multicenter phase 2 QUADRA trial that evaluated the safety and activity of Zejula in 463 patients.
Artificial Intelligence Predicts Survival in Epithelial Ovarian Cancer
Radiomic Prognostic Vector IDs patients with median overall survival of less than 2 years.
Cancer Screening Nonadherence May Be Associated With Increase in Overall Mortality
Nonadherence to protocol screenings in a screening trial for multiple cancers may be linked to higher overall mortality, excluding mortality due to cancers studied in the trial.
Lynparza OK’d as First-Line Maintenance of BRCA-Mutated Advanced Ovarian CA
Lynparza, a poly (ADP-ribose) polymerase (PARP) inhibitor is already approved to treat certain breast, epithelial ovarian, fallopian tube or primary peritoneal cancers based on an FDA-approved companion diagnostic.
-
Loading...
-
Loading...
Next post in Oncology
